
Pacira BioSciences, Inc.: updates and filings
Price
$36.48
November 16, 2026Market cap $1.5B
What Ploutos Investor adds for Pacira BioSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Aug 4, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
- 17TueNoteMaterial agreement entered, material agreement ended, acquisition or disposal of assets, event accelerating an obligation, delisting notice, change to shareholders' rights, change in control, officer or director change, amended articles or bylaws, Regulation FD disclosureDocument
- 5ThuReportQuarterly report · for the period to Sep 30, 2026Document
August 2026
June 2026
April 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026FilingFormS-8 POS
- Nov 17, 2026Material agreement entered, material agreement ended, acquisition or disposal of assets, event accelerating an obligation, delisting notice, change to shareholders' rights, change in control, officer or director change, amended articles or bylaws, Regulation FD disclosureForm8-K
- Nov 17, 2026Filing (amendment)FormSC 14D9/A
- Nov 17, 2026Filing (amendment)FormSC TO-T/A
- Nov 17, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- Nov 12, 2026Regulation FD disclosureForm8-K
- Nov 12, 2026Filing (amendment)FormSC TO-T/A
- Nov 12, 2026Filing (amendment)FormSC 14D9/A
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Regulation FD disclosureForm8-K
- Nov 3, 2026Filing (amendment)FormSC 14D9/A
- Oct 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 30, 2026FilingFormSC 14D9
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | S-8 POS | Filing | Document |
| Nov 17, 2026 | 8-K | Material agreement entered, material agreement ended, acquisition or disposal of assets, event accelerating an obligation, delisting notice, change to shareholders' rights, change in control, officer or director change, amended articles or bylaws, Regulation FD disclosure | Document |
| Nov 17, 2026 | SC 14D9/A | Filing (amendment) | Document |
| Nov 17, 2026 | SC TO-T/A | Filing (amendment) | Document |
| Nov 17, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| Nov 12, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 12, 2026 | SC TO-T/A | Filing (amendment) | Document |
| Nov 12, 2026 | SC 14D9/A | Filing (amendment) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 3, 2026 | SC 14D9/A | Filing (amendment) | Document |
| Oct 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 30, 2026 | SC 14D9 | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 16, 2007.
The full analysis
What do Pacira BioSciences's filings show?
The filings are where every one of Pacira BioSciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.